Profile data is unavailable for this security.
About the company
Embecta Corp. is a global diabetes care company. It is focused on providing solutions to people living with diabetes. It has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It has clearance from the FDA for its proprietary disposable insulin delivery system, which is indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D).
- Revenue in USD (TTM)1.08bn
- Net income in USD139.50m
- Incorporated2021
- Employees1.85k
- LocationEmbecta Corp300 Kimball Drive, Suite 300PARSIPPANY NJ 07054United StatesUSA
- Phone+1 (862) 401-0000
- Fax+1 (302) 655-5049
- Websitehttps://www.embecta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Standard Biotools Inc | 128.83m | -109.46m | 476.86m | 818.00 | -- | 1.19 | -- | 3.70 | -0.289 | -0.3383 | 0.3399 | 1.04 | 0.211 | 1.97 | 5.27 | 157,490.20 | -17.93 | -29.45 | -22.06 | -35.68 | 47.94 | 50.11 | -84.97 | -79.68 | 4.14 | -- | 0.0008 | -- | 64.03 | 8.27 | -147.67 | -- | 26.98 | -- |
| Neuropace Inc | 94.86m | -23.99m | 505.49m | 209.00 | -- | 27.46 | -- | 5.33 | -0.7535 | -0.7535 | 2.98 | 0.5564 | 0.9321 | 1.46 | 7.16 | 515,565.20 | -23.57 | -35.71 | -28.36 | -44.34 | 76.77 | 73.39 | -25.28 | -60.45 | 3.94 | -3.58 | 0.7603 | -- | 22.14 | 16.67 | 17.64 | -- | -8.15 | -- |
| Mesa Laboratories Inc | 247.54m | 3.73m | 508.01m | 730.00 | 142.10 | 2.72 | 17.67 | 2.05 | 0.6471 | 0.6471 | 44.81 | 33.79 | 0.5678 | 3.40 | 6.28 | 339,097.30 | 0.8564 | -8.81 | 1.13 | -9.71 | 62.40 | 61.98 | 1.51 | -25.15 | 1.45 | 1.62 | 0.4709 | -- | 11.47 | 15.41 | 99.22 | -- | 24.60 | 0.00 |
| Orthofix Medical Inc | 818.06m | -119.12m | 529.45m | 1.62k | -- | 1.19 | -- | 0.6472 | -3.04 | -3.04 | 20.82 | 11.20 | 0.9622 | 1.37 | 6.40 | 506,224.00 | -14.01 | -10.81 | -17.28 | -13.34 | 68.27 | 70.31 | -14.56 | -11.57 | 1.38 | -1.35 | 0.2837 | -- | 7.08 | 11.69 | 16.78 | -- | 8.75 | -- |
| Anteris Technologies Global Corp | 2.14m | -84.32m | 531.03m | 136.00 | -- | 56.46 | -- | 248.25 | -2.34 | -2.34 | 0.0594 | 0.1025 | 0.1065 | 1.53 | 11.88 | 15,728.75 | -420.16 | -- | -1,527.00 | -- | 67.94 | -- | -3,945.70 | -- | 0.8032 | -- | 0.046 | -- | -1.16 | -- | -65.77 | -- | -- | -- |
| Pacific Biosciences of California Inc | 154.58m | -503.63m | 546.45m | 575.00 | -- | 15.14 | -- | 3.53 | -1.69 | -1.69 | 0.5236 | 0.1196 | 0.1372 | 1.80 | 5.15 | 268,841.80 | -44.70 | -16.31 | -47.29 | -17.71 | 30.95 | 34.48 | -325.80 | -156.40 | 5.40 | -19.94 | 0.947 | -- | -23.19 | 11.12 | -1.02 | -- | 16.89 | -- |
| Cytek Biosciences Inc | 196.83m | -12.82m | 551.10m | 692.00 | -- | 1.46 | -- | 2.80 | -0.1011 | -0.1011 | 1.54 | 2.96 | 0.3992 | 1.86 | 3.60 | 303,746.90 | -2.60 | 0.3407 | -3.02 | 0.3811 | 53.46 | 58.12 | -6.51 | 0.8678 | 4.48 | -- | 0.0213 | -- | 3.85 | 28.20 | 50.44 | -- | 30.83 | -- |
| Varex Imaging Corp | 844.60m | -70.30m | 593.16m | 2.40k | -- | 1.25 | -- | 0.7023 | -1.70 | -1.70 | 19.25 | 11.34 | 0.7267 | 1.96 | 5.37 | 351,916.70 | -6.01 | -0.3327 | -7.31 | -0.3955 | 34.39 | 33.16 | -8.28 | -0.4661 | 1.83 | 2.45 | 0.4343 | -- | 4.14 | 2.73 | -47.38 | -- | -0.5159 | -- |
| Embecta Corp | 1.08bn | 139.50m | 609.37m | 1.85k | 4.35 | -- | 3.36 | 0.5644 | 2.37 | 2.37 | 18.31 | -10.35 | 0.9757 | 2.27 | 6.35 | 583,621.60 | 12.61 | 16.69 | 16.60 | 22.65 | 63.17 | 66.74 | 12.92 | 15.71 | 1.87 | 3.18 | 1.79 | 13.07 | -3.80 | -0.1033 | 21.84 | -25.93 | -26.03 | -- |
| Tactile Systems Technology Inc | 311.51m | 18.17m | 618.03m | 1.04k | 35.62 | 3.02 | 24.82 | 1.98 | 0.7768 | 0.7768 | 13.28 | 9.18 | 1.14 | 8.38 | 8.07 | 300,398.30 | 6.64 | 1.29 | 7.72 | 1.55 | 49.87 | 49.12 | 5.83 | 1.26 | 3.20 | -- | 0.00 | 0.00 | 6.76 | 9.11 | -40.52 | 9.10 | -15.97 | -- |
| Alpha Tau Medical Ltd | 0.00 | -39.97m | 627.54m | 125.00 | -- | 8.09 | -- | -- | -0.5212 | -0.5212 | 0.00 | 0.9099 | 0.00 | -- | -- | 0.00 | -40.90 | -34.28 | -44.43 | -36.47 | -- | -- | -- | -- | -- | -- | 0.0735 | -- | -- | -- | -8.89 | -- | 11.60 | -- |
| Beta Bionics Inc | 88.57m | -77.84m | 650.68m | 404.00 | -- | 2.21 | -- | 7.35 | -2.07 | -2.07 | 2.21 | 6.70 | 0.4149 | 2.54 | 8.16 | 304,364.30 | -36.46 | -- | -40.57 | -- | 54.51 | -- | -87.89 | -- | 9.83 | -- | 0.00 | -- | 442.93 | -- | -24.17 | -- | -- | -- |
| Bioventus Inc | 563.83m | 7.82m | 667.90m | 950.00 | 71.84 | 4.02 | 11.64 | 1.18 | 0.1123 | 0.1123 | 8.39 | 2.01 | 0.7666 | 1.95 | 4.47 | 606,267.80 | 1.31 | -6.29 | 1.89 | -8.49 | 67.76 | 67.40 | 1.71 | -12.07 | 1.14 | 1.73 | 0.616 | -- | 11.89 | 11.00 | 65.33 | -- | -15.55 | -- |
| SI-Bone Inc | 193.58m | -21.76m | 668.23m | 349.00 | -- | 3.87 | -- | 3.45 | -0.5113 | -0.5113 | 4.55 | 3.98 | 0.8393 | 1.29 | 7.53 | 554,664.80 | -9.43 | -24.17 | -10.61 | -26.87 | 79.62 | 82.72 | -11.24 | -40.93 | 6.62 | -- | 0.1711 | -- | 20.37 | 19.96 | 28.67 | -- | 33.83 | -- |
| Avanos Medical Inc | 699.90m | -468.60m | 683.29m | 2.23k | -- | 0.8782 | -- | 0.9763 | -10.18 | -10.18 | 15.09 | 16.76 | 0.5139 | 2.14 | 5.76 | 314,279.30 | -34.41 | -4.82 | -39.66 | -5.42 | 52.28 | 54.01 | -66.95 | -11.32 | 1.36 | 8.92 | 0.1167 | -- | 2.15 | -0.2826 | -3,802.02 | -- | -18.86 | -- |
Data as of Feb 10 2026. Currency figures normalised to Embecta Corp's reporting currency: US Dollar USD
53.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 7.89m | 13.32% |
| American Century Investment Management, Inc.as of 30 Sep 2025 | 5.19m | 8.76% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.05m | 6.84% |
| River Road Asset Management LLCas of 30 Sep 2025 | 3.25m | 5.48% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.33m | 3.93% |
| Yacktman Asset Management LPas of 31 Dec 2025 | 2.26m | 3.82% |
| Jefferies Investment Advisers LLCas of 30 Sep 2025 | 1.88m | 3.18% |
| William Blair Investment Management LLCas of 30 Sep 2025 | 1.68m | 2.84% |
| Millennium Management LLCas of 30 Sep 2025 | 1.44m | 2.43% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.43m | 2.41% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
